Journal Club: Macrophage-derived fibronectin suppresses antitumor immunity via tissue stiffening and immunosuppressive cell induction in cancer mouse models

by Kaykobad Hossain

This week’s journal club focuses on a study from Nature Communications (2026) highlighting macrophage-derived FN1 as a mechanical cue for aggravating immunosuppression in non-small cell lung cancer.

Following surgical interventions, immunotherapy has become very common approach to be used as antitumor therapy in recent years. However, immunotherapy has had limited success when it comes to treating solid tumor.  One of the contributing factors towards this insufficient therapeutic effect is the tumor microenvironment (TME). Extracellular matrix (ECM) remodeling and stiffening in TME restrict the infiltration of T cells in solid tumor and thus inhibit the functions of cytotoxic T cells. The researchers in this article investigated the role of fibronectin-1 (FN1) secreting tumor associated macrophages (TAMs) in ECM stiffening in non-small cell lung cancer (NSCLC).

The single-cell RNA sequencing analysis of primary NSCLC tumors identified macrophages as a vital source of FN1. The researchers also used flow cytometry and multiplex immunohistochemistry to validate the expression of FN1 by tumor macrophages. In addition, FN1-high macrophages were also reported to be associated with higher immunosuppressive phenotype.

FN1 is an extracellular-matrix protein that interacts with other extracellular components, such as collagen, and organizes the matrix. In this article, the researchers have generated a mouse model where the macrophages did not express FN1 and these mice had lower mechanical stiffness in ECM compared to the control mice. Moreover, the tumors lacking FN1 expression had substantially higher infiltration by T cells, such as CD8+ and CD4+ cells. To further investigate this, they used 3D matrix system where they added CXCL9, a strong T-cell-recruiting chemokine. However, even when the chemotactic signal was present, T cells infiltrated the FN1-deficient matrix more efficiently. This indicates that the physical properties of the matrix themselves might be contributing to immune exclusion. 

More investigation on FN1 activity also demonstrated its function within the macrophages. FN1 promotes cytoskeletal assembly which affects RAC1-mTOR pathway and eventually induce immunosuppressive macrophage state through increased autophagy and reduced glycolysis.

Next, the researchers used an anti-PD-1 immune checkpoint inhibitor in mice lacking FN1 expression by macrophages and in mice with FN1 expressing macrophages. The combination of macrophage FN1 deficiency + anti-PD-1 produced stronger tumor control and longer survival than anti-PD-1 treatment in control mice. The FN1-deficient tumors had more CD8⁺ and NK cells and greater expression of cytotoxic molecules such as perforin and granzyme B.

In short, the article identified FN1 expressed by TAM as a mechanical cue for aggravating immunosuppressive phenotype in NSCLC and highlighted FN1 as intervention target to supplement immunotherapy. 

 

from Li et al. https://www.nature.com/articles/s41467-026-73287-7

Continue your reading  here:

Macrophage-derived fibronectin suppresses antitumor immunity via tissue stiffening and immunosuppressive cell induction in cancer mouse models.
Li A, Wang Y, Bai H, Xie X, Xu B, Wang Y, Luo S, Zhang L, Zhao Q, Duan S, Zhao H, Sun Y, Yuan YC, Wang X, Qiao Q, Cui J, Zhou C, Wang H, Yang L, Yang Y, Si L, Zhang Y, Yang L.

Nat Commun 17, 7296 (2026). https://doi.org/10.1038/s41467-026-73287-7

Leave a Reply

Your email address will not be published. Required fields are marked *